Tags : business


Lonza to Divest Specialty Ingredients Business to Bain Capital and

Shots: Bain Capital and Cinven to acquire Lonza’s specialty ingredients business and operations for an enterprise value of $4.7B. The transaction is expected to close in H2’21 The divestiture will allow Lonza to refocus its business as a pure-play partner to the healthcare industry Lonza’s specialty ingredients business provides microbial control solutions for Professional Hygiene […]Read More


Servier to Acquire Agios’ Oncology Business for ~$2B

Shots: Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through the loss of exclusivity and 15% royalties on sales of vorasidenib in the US from first commercial sale through the loss of exclusivity The acquisition […]Read More


STADA Acquires GSK’s Consumer Healthcare Portfolio to Expand its OTC

Shots: STADA to acquire GSK’s 15 well-established consumer healthcare brands including Venoruton, for venous treatment, Coldrex cold remedy, Cetebe vitamin C supplements, Mebucaine sore throat range and Tavegyl allergy brand The acquisition will strengthen STADA’s OTC portfolio and accelerates its growth in European countries. The transaction is expected to be completed in Q2’2020 The acquisition […]Read More


Perrigo to Separate its Prescription Pharmaceutical Business

Shots:   Perrigo’s separated business helps it to lead the main focus on consumer business, which includes generic medicines including topical creams, foams, mousses, gels, liquids and inhalable products   It may include a tax-efficient separation to shareholders, a sale or merger with no assurance as to form and timing of transaction This separation of […]Read More